Female and male partner age and menotrophin requirements influence pregnancy rates with human menopausal gonadotrophin therapy in combination with intrauterine insemination

This study analyses the influence of female and male patient age and humanmenopausal gonadotrophin (HMG) requirements on clinical pregnancy rates andlive birth rates with ovulation stimulation using HMG in combination withintrauterine insemination (IUI). In this study, 363 consecutive HMG/IUItreatment cycles in 184 patients carried out at a university fertilitycentre were analysed in a retrospective fashion. The main outcomes measuredwere clinical pregnancy rates and live birth rates. Increased femalepartner age (> or = 35) and male partner age (> or = 40) were foundto negatively influence pregnancy rates with HMG/ IUI therapy. In addition,this study demonstrated a critical threshold of HMG requirements beyondwhich pregnancy did not occur. No pregnancies occurred in treatment cyclesrequiring > 25 ampoules (1875 IU) of menotrophins to achieve follicularmaturity, irrespective of patient age. In conclusion, female partner age,male partner age, and HMG requirements all significantly influencepregnancy rates with HMG/IUI therapy.